Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
Study sponsor: BioXcel Therapeutics Inc
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-08-15Actual
Enrollment · participants452Actual
Source updated2026-08-07Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.